A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)

Timeline

Start

2004-09

Primary completion

2005-02

Completion

—

Outcome

Outcome not reported

Stopped: “The biological effect seen with natalizumab was not sufficient to warrant further development in RA.”

Drugs

Indications